Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 2/2015

01-03-2015 | Original Article

Utility of one-step nucleic acid amplification (OSNA) assay in detecting breast cancer metastases of sentinel lymph nodes in a Chinese population

Authors: Dali Li, Xiaoli Xu, Jiajian Chen, Jiaying Chen, Benlong Yang, Wentao Yang, Weiping Xu, Jiong Wu, Daren Shi

Published in: Breast Cancer | Issue 2/2015

Login to get access

Abstract

Background

The one-step nucleic acid amplification (OSNA) assay is an innovative method for the diagnosis of sentinel lymph node (SLN) metastases in breast cancer patients. The aim of the present study was to clinically validate the OSNA assay and compare its results with postoperative serial sectioning in a Chinese breast cancer population.

Methods

A prospective study of 370 consecutive SLNs from 115 patients was conducted at our institution. A total of 311 SLNs underwent OSNA assay analysis. All SLNs were sectioned in approximately 2-mm pieces. OSNA assay and postoperative serial sectioning were performed on alternate divided node samples. The postoperative serial sectioning histology diagnosis was used as the standard.

Results

The overall rate of agreement between OSNA assay and the postoperative serial sectioning was 95.2 % [95 % confidence interval (CI) 91.6–96.9 %], with a sensitivity of 83.3 % (95 % CI 66.5–93.0 %), a specificity of 96.7 % (95 % CI 93.7–98.4 %), a positive predictive value of 76.9 % (95 % CI 60.3–88.3 %), and a negative predictive value of 97.8 % (95 % CI 95.0–99.1 %) based on the number of SLNs sampled before the discordant cases analyses. Eleven out of 15 discordant cases can be explained by tissue allocation bias.

Conclusions

Our study shows that the OSNA assay is more standardized, objective, and reproducible and can utilize more lymphoid tissue than the traditional pathological examination methods. OSNA can also distinguish between micrometastasis and macrometastasis, thereby enabling us to further study the significance of micrometastasis. Since there is a lack of standardization and reproducibility of pathological examination and diagnostic criteria of the SLNs, we recommend that the OSNA assay can be used in daily clinical diagnostic work.
Literature
1.
Cserni G, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, et al. Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol. 2004;57(7):695–701.CrossRefPubMedCentralPubMed
2.
Julian TB, Blumencranz P, Deck K, Whitworth P, Berry DA, Berry SM, et al. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol. 2008;26(20):3338–45.CrossRefPubMed
3.
Wang YS, Liu YH, Ou-Yang T, Yang XH, Wu J, Su FX, et al. GeneSearch™ BLN Assay could replace frozen section and touch imprint cytology for intra-operative assessment of breast sentinel lymph nodes. Breast Cancer. 2013. doi:10.​1007/​s12282-012-0437-z.
4.
Tamaki Y, Akiyama F, Iwase T, Kaneko T, Tsuda H, Sato K, et al. Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res. 2009;15(8):2879–84.CrossRefPubMed
5.
Feldman S, Krishnamurthy S, Gillanders W, Gittleman M, Beitsch PD, Young PR, et al. A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer. 2011;117(12):2599–607.CrossRefPubMed
6.
Le Frère-Belda MA, Bats AS, Gillaizeau F, Poulet B, Clough KB, Nos C, et al. Diagnostic performance of one-step nucleic acid amplification for intraoperative sentinel node metastasis detection in breast cancer patients. Int J Cancer. 2012;130(10):2377–86.CrossRefPubMed
7.
Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, et al. One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 2007;13(16):4807–16.CrossRefPubMed
8.
Snook KL, Layer GT, Jackson PA, de Vries CS, Shousha S, Sinnett HD, et al. Multicentre evaluation of intraoperative molecular analysis of sentinel lymph nodes in breast carcinoma. Br J Surg. 2011;98(4):527–35.CrossRefPubMed
9.
Bernet L, Cano R, Martinez M, Duenas B, Matias-Guiu X, Morell L, et al. Diagnosis of the sentinel lymph node in breast cancer: a reproducible molecular method: a multicentric Spanish study. Histopathology. 2011;58(6):863–9.CrossRefPubMed
10.
Osako T, Iwase T, Kimura K, Yamashita K, Horii R, Yanagisawa A, et al. Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer: a comparative analysis between one-step nucleic acid amplification whole node assay and routine frozen section histology. Cancer. 2011;117(19):4365–74.CrossRefPubMed
11.
Schem C, Maass N, Bauerschlag DO, Carstensen MH, Loning T, Roder C, et al. One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. Virchows Arch. 2009;454(2):203–10.CrossRefPubMed
12.
Visser M, Jiwa M, Horstman A, Brink AA, Pol RP, van Diest P, et al. Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. Int J Cancer. 2008;122(11):2562–7.CrossRefPubMedCentralPubMed
13.
Chen JJ, Huang XY, Liu ZB, Chen TW, Cheng JY, Yang WT, et al. Sentinel node biopsy and quality of life measures in a Chinese population. Eur J Surg Oncol. 2009;35(9):921–7.CrossRefPubMed
14.
Cserni G, Bianchi S, Vezzosi V, van Diest P, van Deurzen C, Sejben I, et al. Variations in sentinel node isolated tumour cells/micrometastasis and non-sentinel node involvement rates according to different interpretations of the TNM definitions. Eur J Cancer. 2008;44(15):2185–91.CrossRefPubMed
15.
Sagara Y, Ohi Y, Matsukata A, Yotsumoto D, Baba S, Tamada S, et al. Clinical application of the one-step nucleic acid amplification method to detect sentinel lymph node metastasis in breast cancer. Breast Cancer. 2011. doi:10.​1007/​s12282-011-0324-z.
16.
Laia BV, Marcos MB, Refael CM, Francisco SC, Jose T, Blai BS, et al. Molecular diagnosis of sentinel lymph nodes for breast cancer: one step ahead for standardization. Diagn Mol Pathol. 2011;20(1):18–21.CrossRefPubMed
17.
Godey F, Leveque J, Tas P, Gandon G, Poree P, Mesbah H, et al. Sentinel lymph node analysis in breast cancer: contribution of one-step nucleic acid amplification (OSNA). Breast Cancer Res Treat. 2012;131(2):509–16.CrossRefPubMed
18.
Castellano I, Macri L, Deambrogio C, Balmativola D, Bussone R, Ala A, et al. Reliability of whole sentinel lymph node analysis by one-step nucleic acid amplification for intraoperative diagnosis of breast cancer metastases. Ann Surg. 2012;255(2):334–42.CrossRefPubMed
19.
Osako T, Iwase T, Kimura K, Yamashita K, Horii R, Akiyama F. Accurate staging of axillary lymph nodes from breast cancer patients using a novel molecular method. Br J Cancer. 2011;105(8):1197–202.CrossRefPubMedCentralPubMed
20.
Cserni G. Intraoperative analysis of sentinel lymph nodes in breast cancer by one-step nucleic acid amplification. J Clin Pathol. 2012;65(3):193–9.CrossRefPubMed
21.
Cox CE, Kiluk JV, Riker AI, Cox JM, Allred N, Ramos DC, et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg. 2008;206(2):261–8.CrossRefPubMed
22.
Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg. 2009;208(3):333–40.CrossRefPubMed
23.
Calhoun KE, Hansen NM, Turner RR, Giuliano AE. Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection. Am J Surg. 2005;190(4):588–91.CrossRefPubMed
24.
Houvenaeghel G, Nos C, Mignotte H, Classe JM, Giard S, Rouanet P, et al. Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement—Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer. J Clin Oncol. 2006;24(12):1814–22.CrossRefPubMed
25.
Lyman GH, Giuliano AE, Somerfield MR, Benson AR, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703–20.CrossRefPubMed
26.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.CrossRefPubMed
Metadata
Title
Utility of one-step nucleic acid amplification (OSNA) assay in detecting breast cancer metastases of sentinel lymph nodes in a Chinese population
Authors
Dali Li
Xiaoli Xu
Jiajian Chen
Jiaying Chen
Benlong Yang
Wentao Yang
Weiping Xu
Jiong Wu
Daren Shi
Publication date
01-03-2015
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2015
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-013-0461-7

Other articles of this Issue 2/2015

Breast Cancer 2/2015 Go to the issue

Original Article

Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer

Original Article

Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma

Case Report

Malignant lymphoma of the breast in a male patient: ultrasound imaging features

Original Article

Divisional role of quantitative HER2 testing in breast cancer

Editorial

Z-11 trial and rethinking axillary reverse mapping

Original Article

A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits